RU2558301C2 - Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие - Google Patents

Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие Download PDF

Info

Publication number
RU2558301C2
RU2558301C2 RU2012118598/10A RU2012118598A RU2558301C2 RU 2558301 C2 RU2558301 C2 RU 2558301C2 RU 2012118598/10 A RU2012118598/10 A RU 2012118598/10A RU 2012118598 A RU2012118598 A RU 2012118598A RU 2558301 C2 RU2558301 C2 RU 2558301C2
Authority
RU
Russia
Prior art keywords
seq
rage
antibody
amino acid
acid sequence
Prior art date
Application number
RU2012118598/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012118598A (ru
Inventor
Йохен ХУБЕР
Франсис БЛАНШ
Тарик ДАБДУБИ
Фабьенн СУБРИЕ
Инго ФОККЕН
Йохен КРУИП
Катрин ХЕЕРМАЙЕР
Кристиан ЛАНГЕ
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/en
Priority claimed from EP09290845A external-priority patent/EP2319871A1/en
Application filed by Санофи filed Critical Санофи
Publication of RU2012118598A publication Critical patent/RU2012118598A/ru
Application granted granted Critical
Publication of RU2558301C2 publication Critical patent/RU2558301C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
RU2012118598/10A 2009-10-09 2010-10-08 Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие RU2558301C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09290778.1 2009-10-09
EP09290778A EP2308896A1 (en) 2009-10-09 2009-10-09 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845A EP2319871A1 (en) 2009-11-05 2009-11-05 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845.8 2009-11-05
PCT/EP2010/065124 WO2011042548A1 (en) 2009-10-09 2010-10-08 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Publications (2)

Publication Number Publication Date
RU2012118598A RU2012118598A (ru) 2013-11-20
RU2558301C2 true RU2558301C2 (ru) 2015-07-27

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012118598/10A RU2558301C2 (ru) 2009-10-09 2010-10-08 Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие

Country Status (20)

Country Link
US (1) US20120282637A1 (enExample)
EP (1) EP2486058A1 (enExample)
JP (1) JP2013507115A (enExample)
KR (1) KR20120089863A (enExample)
CN (1) CN102686611A (enExample)
AU (1) AU2010305374A1 (enExample)
BR (1) BR112012007821A2 (enExample)
CA (1) CA2777237A1 (enExample)
CL (1) CL2012000886A1 (enExample)
CR (1) CR20120139A (enExample)
EC (1) ECSP12011787A (enExample)
IL (1) IL218968A0 (enExample)
MA (1) MA33661B1 (enExample)
MX (1) MX2012004090A (enExample)
PE (1) PE20121689A1 (enExample)
PH (1) PH12012500564A1 (enExample)
RU (1) RU2558301C2 (enExample)
TN (1) TN2012000138A1 (enExample)
WO (1) WO2011042548A1 (enExample)
ZA (1) ZA201202099B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (ja) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 アミロイド前駆体タンパク質のα－セクレターゼ切断後のＣ末端側断片の切断面を特異的に認識する抗体及びその利用
US11668721B2 (en) * 2013-06-04 2023-06-06 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
WO2015085097A1 (en) 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US20170240632A1 (en) * 2014-10-16 2017-08-24 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
ES3063952T3 (en) 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
US20180355033A1 (en) 2015-06-10 2018-12-13 Dana-Farber Cancer Institute, Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2016201319A1 (en) * 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
PE20181051A1 (es) * 2015-09-08 2018-07-03 Eisai Randd Man Co Ltd Anticuerpo anti-epha4
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN113512111B (zh) * 2017-03-10 2023-08-15 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
MX2020001309A (es) * 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CA3143211A1 (en) * 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
WO2023092082A1 (en) * 2021-11-18 2023-05-25 Bentley Cornelia Antibodies to receptor of advanced glycation end products (rage) and uses thereof
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用
KR20250001879A (ko) 2023-06-28 2025-01-07 주식회사 세바바이오텍 완도호랑가시나무와 노루궁뎅이버섯 추출물을 유효성분으로 포함하는 최종당화산물 억제용 조성물
CN122036956B (zh) * 2026-04-20 2026-07-17 中南大学湘雅三医院 一种非联苯四唑沙坦类药物的单克隆抗体、核酸分子、检测试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2219947C2 (ru) * 1997-09-18 2003-12-27 Айдек Фармасьютикалз Корпорейшн Синергическая композиция и способы лечения состояний неопластического или злокачественного роста и восстановления или усиления гемопоэза
WO2008137552A3 (en) * 2007-05-02 2009-01-08 Medimmune Llc Anti-rage antibodies and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1390494A2 (en) 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20090155799A1 (en) * 2006-03-02 2009-06-18 Yusuke Nakamura Methods for diagnosing pancreatic cancer using reg4 protein
MX2008011933A (es) * 2006-03-21 2008-12-18 Wyeth Corp Metodos y composiciones para antagonismo de rage.
CN101405300A (zh) * 2006-03-21 2009-04-08 惠氏公司 用于拮抗rage的方法及组合物
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
CN102089430B (zh) * 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2219947C2 (ru) * 1997-09-18 2003-12-27 Айдек Фармасьютикалз Корпорейшн Синергическая композиция и способы лечения состояний неопластического или злокачественного роста и восстановления или усиления гемопоэза
WO2008137552A3 (en) * 2007-05-02 2009-01-08 Medimmune Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL218968A0 (en) 2012-07-31
PH12012500564A1 (en) 2012-10-22
WO2011042548A1 (en) 2011-04-14
KR20120089863A (ko) 2012-08-14
JP2013507115A (ja) 2013-03-04
MA33661B1 (fr) 2012-10-01
ZA201202099B (en) 2012-11-28
CA2777237A1 (en) 2011-04-14
AU2010305374A1 (en) 2012-05-03
TN2012000138A1 (en) 2013-09-19
CN102686611A (zh) 2012-09-19
ECSP12011787A (es) 2012-10-30
MX2012004090A (es) 2012-04-20
PE20121689A1 (es) 2012-12-14
EP2486058A1 (en) 2012-08-15
BR112012007821A2 (pt) 2017-05-30
US20120282637A1 (en) 2012-11-08
CL2012000886A1 (es) 2012-12-14
RU2012118598A (ru) 2013-11-20
CR20120139A (es) 2012-07-13

Similar Documents

Publication Publication Date Title
US20120282637A1 (en) Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving
CN112646031B (zh) 抗4-1bb纳米抗体及其用途
JP7215759B2 (ja) ４－１ｂｂ抗体およびその製造方法と使用
TWI767899B (zh) Psma及cd3雙特異性t細胞嚙合抗體構築體
KR102658637B1 (ko) T 세포 관여 항체 구축물을 포함하는 저 pH 약제학적 조성물
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
AU2019314999A1 (en) Antibody constructs for CLDN18.2 and CD3
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
JP7805362B2 (ja) Ｃｄ３に結合するポリペプチド構築物
AU2021374036A1 (en) Polypeptide constructs selectively binding to cldn6 and cd3
CN110938146B (zh) Tim-3单域抗体及其应用
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
US20230406887A1 (en) Antigen binding domain with reduced clipping rate
KR20250160321A (ko) 항-메소텔린 항체 및 이의 용도
US20230242640A1 (en) ANTI-SIRPg Compounds
EP2319871A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2308896A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
EA050517B1 (ru) Антигенсвязывающий домен с пониженной скоростью расщепления
CN121181702A (zh) 一种抗epha2的抗体及其相关应用
CN115710309A (zh) 新冠病毒广谱中和性单克隆抗体的制备和应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161009